沙利度胺联合奈达铂治疗非小细胞肺癌的临床疗效

Curative efficacy of thalidomide combination with nedaplatin in the treatment of non-small cell lung cancer

目的探讨沙利度胺联合奈达铂治疗非小细胞肺癌（NSCLC）的临床疗效。方法选取2013年1月至2014年10月间收治的108例NSCLC患者作为研究对象,按照随机数字表法,将患者随机分为观察组和对照组,每组各54例。观察组患者采用奈达铂＋沙利度胺治疗,对照组患者给予奈达铂治疗。比较两组患者的近期疗效、血清血管内皮生长因子（VEGF）、碱性成纤维生长因子（b FGF）、肿瘤坏死因子α（TNF-α）水平及不良反应。结果观察组患者近期治疗有效率为40.7%,与对照组（31.5%）比较,差异无统计学意义（P〉0.05）。治疗后,观察组患者血清VEGF、b FGF、TNF-α水平均低于对照组,差异均有统计学意义（P〈0.05）。观察组患者Ⅰ～Ⅱ度胃肠道不良反应发生率低于对照组,差异有统计学意义（P〈0.05）,而中性粒细胞减少、血红蛋白减少、血小板减少、肝功能损害等不良反应发生率差异均无统计学意义（均P〉0.05）。结论沙利度胺联合奈达铂治疗NSCLC疗效确切,能够显著降低胃肠道不良反应发生率及血清VEGF、b FGF、TNF-α水平,临床上值得推广。

Objective To investigate the curative efficacy of thalidomide combination with nedaplatin in the treatment of non-small cell lung cancer（ NSCLC）. Methods Totally 108 cases with NSCLC meeting the inclusion criteria from January 2013 to October 2014 were divided into observation group and control group equally according to random number table. The observation group was treated with thalidomide combination with nedaplatin,while the control group was treated with nedaplatin. Curative efficacy,levels of serum vascular endothelial growth factor（ VEGF）,basic fibroblast growth factor（ b FGF）,tumor necrosis factor（ TNF）-α and toxic side effects were observed and compared. Results The observation group had a total short-term therapeutic efficiency ratio of 40. 7%,had no statistical difference with that of 31. 5% in the control group（ P〉0. 05）. The serum levels of VEGF,b FGF and TNF-α in the observation group were significantly lower than those in the control group after the treatment（ P 005）. As to toxic side effects,the occurrence of gastrointestinal reaction of Ⅰ and Ⅱ degree in the observation group was statistically lower than that in the control group（ P〈0. 05）,while occurrence of neutropenia,decreased hemoglobin,thrombopenia and liver function damage in the two groups had no statistical difference（ P〉0. 05）. Conclusions Thalidomide combination with nedaplatin for NSCLC is effective. And it can significantly decrease occurrence of gastrointestinal reaction and levels of serum VEGF,b FGF and TNF-α.